Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis
Impact of Sex and Smoking on the Efficacy of EGFR-TKIs in Terms of Overall Survival in Non-small-Cell Lung Cancer: A Meta-Analysis
复制标题
性别和吸烟对 EGFR-TKI 对非小细胞肺癌总体生存率的影响：荟萃分析
DOI：
10.3389/fonc.2020.01531
复制
发表时间：
2020-08
影响因子：
4.7
通讯作者：
Qiong Chen
中科院分区：
文献类型：
--
作者：
Jian Xiao;Liang Zhou;Bixiu He;Qiong Chen
背景：全面了解性别和吸烟对表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗非小细胞肺癌(NSCLC)总生存率(OS)的影响。方法：应用计算机检索PubMed、Cochrane图书馆、Embase、Scope，检索时间为2019年3月17日。根据危险比(HR)和95%可信区间(CI)分析OS，并使用随机效应模型进行估计。结果：我们的荟萃分析包括22项研究，涉及11874名患者。初步分析发现，男女间EGFR-TKI干预的疗效差异无统计学意义(合并HR为0.95，95%CI为0.87~1.04，P=0.30)，不吸烟者与有吸烟者之间的疗效差异无统计学意义(合并HR为0.91，95%CI为0.76~1.09，P=0.31)。在安慰剂对照治疗的亚组分析中，我们发现接受EGFR-TKI治疗的女性NSCLC患者的OS比男性患者长(合并HR 0.86，95%CI 0.75-1.00，P=0.04)，而在所有亚组分析中，吸烟状况对NSCLC患者的OS没有显著影响。结论：EGFR-TKI治疗非小细胞肺癌的疗效与吸烟状况无关，但与性别有关，且女性的OS较男性长。
Background: To comprehensively understand the impact of sex and smoking on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in terms of overall survival (OS) in non-small-cell lung cancer (NSCLC). Methods: PubMed, Cochrane Library, Embase, and Scopus were searched from inception to March 17, 2019. OS was analyzed based on hazard ratios (HRs) and 95% confidence intervals (CIs) and estimated using the random effects model. Results: Our meta-analysis included 22 studies involving 11,874 patients. In the primary analysis, we found no statistically significant efficacy difference for EGFR-TKI intervention between females and males (pooled HR 0.95, 95% CI 0.87–1.04, P = 0.30) and no obvious efficacy difference between never smokers and ever smokers (pooled HR 0.91, 95% CI 0.76–1.09, P = 0.31). In the subgroup analysis of placebo control treatment, we found that female NSCLC patients who received EGFR-TKI therapy had a longer OS than male patients (pooled HR 0.86, 95% CI 0.75–1.00, P = 0.04), while smoking status showed no significant effect on the efficacy of EGFR-TKI treatment in terms of the OS of NSCLC patients in all subgroup analyses. Conclusion: The efficacy of EGFR-TKI therapy for NSCLC patients is independent of smoking status but dependent on sex, and females have a longer OS than males.
登录
查看更多内容
影响因子：
7.3
作者：
Pinto JA;Vallejos CS;Raez LE;Mas LA;Ruiz R;Torres-Roman JS;Morante Z;Araujo JM;Gómez HL;Aguilar A;Bretel D;Flores CJ;Rolfo C
通讯作者：
Rolfo C
DOI：
10.1891/9780826121646.0002
发表时间：
2018-09
期刊：
Cancer Rehabilitation
影响因子：
--
作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
通讯作者：
K. Miller;R. Siegel;R. Khan;A. Jemal
影响因子：
3.9
作者：
Lin L;Zhao J;Hu J;Zou G;Huang F;Han J;He Y;Cao X
通讯作者：
Cao X
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
DOI：
--
发表时间：
2003
期刊：
--
影响因子：
--
作者：
J.David Cassidy-;Linda J. Carroll;Pierre Côté;Anita Berglund;Åke Nygren
通讯作者：
J.David Cassidy-;Linda J. Carroll;Pierre Côté;Anita Berglund;Åke Nygren